Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus

Type 2 diabetes mellitus (T2DM) affects an estimated 463 million people worldwide, equivalent to 1 in 11 adults. Moreover, the rapid growth of this disease has resulted in a high incidence of diabetic kidney disease (DKD), which, together with hypertension, is the main cause of chronic kidney diseas...

ver descrição completa

Detalhes bibliográficos
Autores: D’Marco, Luis, Puchades, María Jesús, Gandía, Lorena, Forquet, Claudia, Giménez-Civera, Elena, Panizo, Nayara, Reque, Javier, Juan-García, Isabel, Bermúdez, Valmore, Gorriz, José Luis
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2021
País:Colombia
Recursos:Universidad Simón Bolívar
Repositório:Repositorio Digital USB
Idioma:inglês
OAI Identifier:oai:bonga.unisimon.edu.co:20.500.12442/9655
Acesso em linha:https://hdl.handle.net/20.500.12442/9655
https://doi.org/10.17925/EE.2021.17.2.84
Access Level:Acceso aberto
Palavra-chave:Chronic kidney disease
cardiovascular diseases
diabetic nephropathies
finerenone
id CO_c887833fb28a07d5e8b7319dfd3e560f
oai_identifier_str oai:bonga.unisimon.edu.co:20.500.12442/9655
network_acronym_str CO
network_name_str Colombia
repository_id_str
spelling Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes MellitusD’Marco, LuisPuchades, María JesúsGandía, LorenaForquet, ClaudiaGiménez-Civera, ElenaPanizo, NayaraReque, JavierJuan-García, IsabelBermúdez, ValmoreGorriz, José LuisChronic kidney diseasecardiovascular diseasesdiabetic nephropathiesfinerenoneType 2 diabetes mellitus (T2DM) affects an estimated 463 million people worldwide, equivalent to 1 in 11 adults. Moreover, the rapid growth of this disease has resulted in a high incidence of diabetic kidney disease (DKD), which, together with hypertension, is the main cause of chronic kidney disease (CKD). Hyperglycaemia, low-grade inflammation, altered lipid metabolism and hyperactivation of the renin–angiotensin–aldosterone system (RAAS) seem to be interrelated mechanisms contributing to both T2DM and microvascular complications. The introduction of drugs such as sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists has improved the ability to slow the progression of DKD, and has also demonstrated benefits in cardiovascular disease. Beyond the effects of these novel antidiabetic drugs, a body of evidence suggests that the overactivation of the mineralocorticoid receptor also contributes to CKD progression. Moreover, new and ongoing trials have demonstrated that the selective nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone improves the risk of CKD progression and cardiovascular events in patients with CKD and T2DM and optimized RAAS blockade. We review the rationale for the development and use of MRA drugs to slow CKD progression in patients with DKD, as well as other pleiotropic effects, and highlight the warnings associated with these agents.Touch Medical Media2022-05-10T12:49:58Z2022-05-10T12:49:58Z2021info:eu-repo/semantics/articleArtículo científicoinfo:eu-repo/semantics/publishedVersionpdfapplication/pdf27525457https://hdl.handle.net/20.500.12442/9655https://doi.org/10.17925/EE.2021.17.2.84Vol. 17 Num. 2 (2021)European Endocrinologyreponame:Repositorio Digital USBinstname:Universidad Simón Bolívarinstacron:Universidad Simón BolívarengAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccess2022-05-10T18:18:32Z
dc.title.none.fl_str_mv Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
title Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
spellingShingle Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
D’Marco, Luis
Chronic kidney disease
cardiovascular diseases
diabetic nephropathies
finerenone
title_short Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
title_full Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
title_fullStr Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
title_full_unstemmed Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
title_sort Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
dc.creator.none.fl_str_mv D’Marco, Luis
Puchades, María Jesús
Gandía, Lorena
Forquet, Claudia
Giménez-Civera, Elena
Panizo, Nayara
Reque, Javier
Juan-García, Isabel
Bermúdez, Valmore
Gorriz, José Luis
author D’Marco, Luis
author_facet D’Marco, Luis
Puchades, María Jesús
Gandía, Lorena
Forquet, Claudia
Giménez-Civera, Elena
Panizo, Nayara
Reque, Javier
Juan-García, Isabel
Bermúdez, Valmore
Gorriz, José Luis
author_role author
author2 Puchades, María Jesús
Gandía, Lorena
Forquet, Claudia
Giménez-Civera, Elena
Panizo, Nayara
Reque, Javier
Juan-García, Isabel
Bermúdez, Valmore
Gorriz, José Luis
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Chronic kidney disease
cardiovascular diseases
diabetic nephropathies
finerenone
topic Chronic kidney disease
cardiovascular diseases
diabetic nephropathies
finerenone
description Type 2 diabetes mellitus (T2DM) affects an estimated 463 million people worldwide, equivalent to 1 in 11 adults. Moreover, the rapid growth of this disease has resulted in a high incidence of diabetic kidney disease (DKD), which, together with hypertension, is the main cause of chronic kidney disease (CKD). Hyperglycaemia, low-grade inflammation, altered lipid metabolism and hyperactivation of the renin–angiotensin–aldosterone system (RAAS) seem to be interrelated mechanisms contributing to both T2DM and microvascular complications. The introduction of drugs such as sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists has improved the ability to slow the progression of DKD, and has also demonstrated benefits in cardiovascular disease. Beyond the effects of these novel antidiabetic drugs, a body of evidence suggests that the overactivation of the mineralocorticoid receptor also contributes to CKD progression. Moreover, new and ongoing trials have demonstrated that the selective nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone improves the risk of CKD progression and cardiovascular events in patients with CKD and T2DM and optimized RAAS blockade. We review the rationale for the development and use of MRA drugs to slow CKD progression in patients with DKD, as well as other pleiotropic effects, and highlight the warnings associated with these agents.
publishDate 2021
dc.date.none.fl_str_mv 2021
2022-05-10T12:49:58Z
2022-05-10T12:49:58Z
dc.type.none.fl_str_mv info:eu-repo/semantics/article
Artículo científico
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv 27525457
https://hdl.handle.net/20.500.12442/9655
https://doi.org/10.17925/EE.2021.17.2.84
identifier_str_mv 27525457
url https://hdl.handle.net/20.500.12442/9655
https://doi.org/10.17925/EE.2021.17.2.84
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv pdf
application/pdf
dc.publisher.none.fl_str_mv Touch Medical Media
publisher.none.fl_str_mv Touch Medical Media
dc.source.none.fl_str_mv Vol. 17 Num. 2 (2021)
European Endocrinology
reponame:Repositorio Digital USB
instname:Universidad Simón Bolívar
instacron:Universidad Simón Bolívar
instname_str Universidad Simón Bolívar
instacron_str Universidad Simón Bolívar
institution Universidad Simón Bolívar
reponame_str Repositorio Digital USB
collection Repositorio Digital USB
_version_ 1825051214634549248
score 15,812429

Registros relacionados